Ventolin Shortage Update: What Patients Need to Know in 2026

The albuterol shortage — affecting Ventolin HFA inhalers and albuterol nebulizer solutions — has been one of the most persistent medication access problems of the past few years. If you or someone you care for depends on this life-saving rescue inhaler, here's the most current information on what's happening and what you can do.

Quick Summary: Where Things Stand in 2026

• Ventolin HFA inhalers: Generally available at most retail pharmacies. GlaxoSmithKline continues producing Ventolin HFA, and generic albuterol HFA inhalers from Cipla and Lupin are on the market. Localized stock-outs can still occur.
• Albuterol nebulizer solution: Shortage remains active but is improving. Two new FDA-approved manufacturers (Ritedose, November 2025; Amneal, March 2026) are ramping up production.
• Generic albuterol HFA aerosol: FDA approved Amneal Pharmaceuticals to produce generic albuterol sulfate inhalation aerosol in March 2026 — adding more inhaler supply competition.

Timeline: How the Shortage Developed

Understanding the timeline helps explain why this has lasted so long and why improvement is gradual:

• October 2022: FDA places albuterol sulfate inhalation solution on its official drug shortage list after Akorn Pharmaceuticals stops shipping its 20 mL formulation.
• February 2023: Akorn Pharmaceuticals files for Chapter 7 bankruptcy and shuts down all three U.S. manufacturing plants in New Jersey, New York, and Illinois — removing a critical source of nebulizer solution.
• Spring/Summer 2023: Shortage intensifies as spring allergy season and increased RSV activity drive demand higher. Hospitals begin compounding albuterol or rationing nebulizer doses.
• 2024-2025: FDA works with existing manufacturers to address shortage. New manufacturers begin FDA approval processes. Generic HFA inhaler approvals expand the inhaler supply.
• November 2025: FDA approves Ritedose Pharmaceuticals to manufacture albuterol sulfate inhalation solution 0.5% — adding a new certified producer of nebulizer solution.
• March 2026: FDA approves Amneal Pharmaceuticals for generic albuterol sulfate inhalation aerosol — expanding the inhaler supply. Production ramp-up expected throughout 2026.

Why Did the Shortage Last This Long?

Pharmaceutical economists have long warned about the fragility of the generic drug supply chain. Albuterol, being a low-cost generic with thin margins, attracted fewer manufacturers over time. When Akorn collapsed, there was simply not enough spare capacity elsewhere to absorb the loss quickly. Getting new manufacturers approved and production lines running takes 12-24 months or more — which is why 2022's shortage is still being felt in 2026.

Who Is Most Affected?

The people hardest hit by the ongoing nebulizer solution shortage are:

• Young children (under age 4): Too young to use a standard inhaler. Nebulizers are their primary delivery method.
• Elderly patients: Those who have difficulty coordinating inhaler use (press-and-breathe) rely on nebulizers.
• Hospitalized patients: Emergency departments and ICUs depend on continuous nebulized albuterol for severe asthma and COPD exacerbations.
• Uninsured and underinsured patients: Less financially able to pivot to more expensive alternatives like levalbuterol or brand-name inhalers.

What Should Patients Do Right Now?

Here's a practical action plan for patients dealing with the 2026 Ventolin shortage:

1. Check availability near you. Use medfinder.com to find which pharmacies near you have Ventolin or albuterol in stock. medfinder calls pharmacies on your behalf and texts you the results.
2. Ask for generic. FDA-approved generic albuterol HFA inhalers are therapeutically equivalent to Ventolin HFA and may be in stock when the brand isn't.
3. Refill early. Don't wait until your inhaler runs out. Most insurance allows refills when you're at a 7-10 day supply.
4. Talk to your doctor about alternatives. If you need a nebulizer solution and can't find it, levalbuterol solution or compounded albuterol may be options. Ask your care team.
5. Review your action plan. If you have asthma, review your written asthma action plan with your doctor. Make sure you have clear instructions for what to do in an emergency if your rescue inhaler is unavailable.

Is This Shortage Going to End?

The supply situation is genuinely improving. With Ritedose (November 2025) and Amneal (March 2026) now producing FDA-approved albuterol products, the number of suppliers has grown. As production scales, pharmacy-level availability should continue to improve throughout 2026. However, patients should not assume the problem is fully solved yet — localized stock-outs will still occur. For tips on tracking down your prescription, see: How to Find Ventolin in Stock Near You.